Radicava, (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)

Date Added
September 13th, 2019
PRO Number
Pro00089696
Researcher
Amy Chen

List of Studies


Keywords
Nervous System
Summary

Adult patients with ALS that have been recently perscribed Edaravone may qualify to participate in this observational study. Blood and urine samples will be collected to evaluate the effects of Edaravone on ALS and the severity of ALS. During an estimated 12-month period, eligible participants will have approximately 15 clinic visits.

Institution
MUSC
Recruitment Contact
Katrina Madden
843-792-9186
maddenka@musc.edu



-- OR --